Jiangsu Gensciences lnc. Report issue

For profit Phase 1 Phase 3
Founded: Jiangsu China (2020)

Organization Overview

First Clinical Trial
2020
NCT04456387
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Haimen Gensciences lnc | Jiangsu Gensciences lnc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemophilia A (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2